Medexus Pharmaceuticals Inc.
MDP.TO
TSX
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 18.96% | -13.27% | -13.54% | -9.33% | -12.25% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 18.96% | -13.27% | -13.54% | -9.33% | -12.25% |
| Cost of Revenue | 17.73% | -15.79% | -14.17% | -7.62% | -2.13% |
| Gross Profit | 19.94% | -11.46% | -13.10% | -10.60% | -18.88% |
| SG&A Expenses | 2.61% | -18.66% | -13.03% | -8.97% | -9.98% |
| Depreciation & Amortization | 21.27% | 7.72% | -2.49% | -2.56% | -4.42% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 10.86% | -17.07% | -14.08% | -10.34% | -7.13% |
| Operating Income | 141.14% | 15.36% | -10.54% | -0.07% | -52.08% |
| Income Before Tax | 210.69% | 40.29% | 114.93% | 8,150.00% | 17.19% |
| Income Tax Expenses | 156.32% | -675.83% | -124.46% | 103.33% | -147.71% |
| Earnings from Continuing Operations | 237.27% | 110.06% | 200.61% | -88.89% | 64.57% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 237.27% | 110.06% | 200.61% | -88.89% | 64.57% |
| EBIT | 141.14% | 15.36% | -10.54% | -0.07% | -52.08% |
| EBITDA | 83.59% | 13.14% | -9.31% | 2.89% | -37.00% |
| EPS Basic | 234.39% | 108.41% | 148.45% | -90.93% | 70.61% |
| Normalized Basic EPS | 208.78% | 260.74% | 110.99% | 2,212.12% | -12.02% |
| EPS Diluted | 234.39% | 108.41% | 166.67% | -89.89% | 70.61% |
| Normalized Diluted EPS | 208.78% | 260.74% | 110.99% | 2,373.33% | -12.02% |
| Average Basic Shares Outstanding | 2.04% | 20.14% | 20.90% | 22.63% | 20.68% |
| Average Diluted Shares Outstanding | 2.04% | 20.14% | 20.90% | 13.48% | 20.68% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |